China's Haibote raises $10.5M extension round for clinical CRO push
What's the deal? Guangzhou Haibote Pharmaceutical Technology has raised US$9.63M in a Series B extension round. Yuanyi InvestmentDealroom has a profile for this one. Try Dealroom → led the round, with Guangzhou Health Industry Investment, Wanlian GuangshengDealroom has a profile for this one. Try Dealroom →, Liwan Guangyao Fund, and Jingxi Investment taking part.
What does Haibote do? Founded in 2009, it is a clinical contract research organisation (CRO) that runs Phase I to IV trials for innovative drugs, bioequivalence studies for generics, and medical device trials. Its specialty is post-market re-evaluation and real-world studies for traditional Chinese medicine — a niche where it says it has completed more than 1,250 projects for over 600 clients.
What's the money for? Haibote will invest in AI-assisted trial design, patient enrolment feasibility assessment, and data quality control. The aim is to turn years of clinical execution experience into reusable digital tools.
Why now? The round lands as clinical trial activity in China grows and drugmakers keep outsourcing research. But demand does not lift every CRO equally — clients weigh delivery speed, enrolment pace, and data reliability.
The signal: At roughly $10.5 million, this is a capability-upgrade round, not a blockbuster deal or a sign of sector-wide consolidation. The test is whether faster enrolment and less rework translate into a real edge for a specialist CRO.
Read more: sohu.com
Image credit: Generated with Gemini
